Estimated reading time: 4 minutes
Key Takeaways
- RxSight slashed its 2025 revenue forecast by £40-£50 million, triggering a 50% share price collapse.
- Hardware sales of the Light Delivery Driver (LDD) are faltering, despite resilient lens demand.
- Analysts rushed to downgrade targets; Stifel cut its price objective from £17 to £9.
- Investors now expect revenue contraction in 2025, not growth.
Table of Contents
Market Reaction
Shares of RxSight cratered 50% in a single session after management stunned investors with a sharply lower 2025 outlook. The stock flirted with its 52-week floor of £12.38, leaving it 64 per cent below its spring peak. One trader described the move as “a capitulation moment that forces a reset on the growth story.”
Revenue Revision
Management now expects 2025 revenue of £120-£130 million, down from the prior £160-£175 million guide. In its official filing, the company blamed a slowdown in hardware adoption and tighter capital budgets at clinics.
- Full-year outlook implies a 7-14% y/y decline.
- Q2 2025 revenue slipped 4% year-on-year to £33.6 million and 11% sequentially.
Breaking Down the Numbers
Despite a 13% rise in Light Adjustable Lens (LAL) volumes to 27,380 units, shipments of the higher-margin LDD platform plunged 45% quarter-on-quarter to just 40 units. Gross margin is likely feeling the pinch, while operating costs continue to climb—a toxic combination for cash flow.
“Lens demand is healthy, but the razor-and-blade model breaks when clinics stop buying the razor,” a sell-side analyst warned.
Hardware Challenge
RxSight ended June with 1,084 LDD units in the field, up 34% year-on-year yet well below internal targets. The momentum is clearly fading as more eye-care providers postpone purchases.
- Clinic hesitation tied to capital budgets and uncertainty on patient throughput.
- Management vows “spending discipline” and selective investment until adoption improves.
Analyst Downgrades
In a swift reaction, Stifel cut its target price to £9, citing execution risk. Other brokers maintained “hold” ratings but warned the path to profitability now looks longer.
- Consensus now models a revenue contraction in 2025.
- Street expects negative free cash flow through 2026.
Investment Outlook
With the growth narrative on pause, RxSight now carries a higher-risk profile. Bulls argue the technology remains best-in-class, yet bears counter that execution on hardware penetration is paramount.
- Key catalyst: evidence of stabilisation in LDD shipments over the next two quarters.
- Watch cash burn and any moves to raise capital.
Conclusion
The sudden £40-£50 million haircut to 2025 revenue guidance has wiped out half of RxSight’s market value. Until management revives LDD sales and reins in costs, sentiment is likely to stay fragile—and so will the share price.
FAQs
Why did RxSight cut its 2025 revenue forecast?
Management cited weaker-than-expected demand for the LDD hardware platform and elongated sales cycles at clinics.
How significant was the stock price drop?
The shares fell roughly 50% in one trading day, bringing the total decline from the yearly high to 64%.
Are lens sales still growing?
Yes. Light Adjustable Lens volumes grew 13% year-on-year in Q2 2025, highlighting continued patient demand.
What do analysts expect next?
Most analysts now project revenue contraction in 2025 and are waiting for a rebound in LDD shipments before turning positive.
Is RxSight likely to raise additional capital?
If cash burn accelerates and hardware sales do not recover, a capital raise in 2026 cannot be ruled out.
